Thalassemia Major

Reports summarize thalassemia research from S. Bergeachituv and co-authors

Thalassemia Major Library Library Home This article was published in Biotech Business Week, which you can subscribe to online.

"He continued to be transfusion dependent although chimerism evaluation, using analysis of the beta-globin gene mutation, showed 90-98% donor cells in peripheral leukocytes after 3 months and 82-90% donor cells in the bone marrow after 26 and 30 months. Clinical improvement occurred gradually, and the patient became transfusion free 6 years posttransplant," wrote S. Bergeachituv and colleagues.

The researchers concluded: "We reason that an exceptional slow displacement of host red-blood-cell lineage took place that was not evident from the high level of chimerism found in peripheral leukocytes and bone marrow."

Bergeachituv and colleagues published their study in American Journal of Hematology (Phenotypic cure 6 years after bone marrow transplantation in a beta-thalassemia patient. American Journal of Hematology, 2009;84(6):373-375).

For additional information, contact B. Wolach, Meir Med Center, Dept. of Pediatrics, 59 Tchernichovsky St., IL-44281 Kefar Sava, Israel.

The publisher's contact information for the American Journal of Hematology is: Wiley-Liss, Division John Wiley & Sons Inc., 111 River St., Hoboken, NJ 07030, USA.

Keywords: Israel, Kefar Sava, Beta-Thalassemia, Blood Transfusion, Bone Marrow Transplantation, Hematology, Medical Device, Surgery, Thalassemia, Transfusion Medicine.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.